Type 1 Diabetes Mellitus Clinical Trials in New York, New York

5 studies are recruiting for type 1 diabetes mellitus in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

   This is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase 3, 2-arm study for treatment. The purpose of this study is to measure change in glycemic control and prandial insulin independency over 52 weeks with teplizumab compared with placebo, both administered by intravenou…

   Stage

   Phase 3

   Ages

   1 to 25

   Site

   Endocrine Associates of West Village- Site Number : 8400064, New York, New York

   Locations

   197 in total

   Run by

   Sanofi

   See if you can join NCT07088068 on ClinicalTrials.gov

2. CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)

   This study is a Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-103. The approximately 393-days study consists of a Screening Period (28 days), Treatment Period (90 days), and Post-Dose Evalua…

   Stage

   Phase 1

   Ages

   12 to 35

   Site

   Hassenfield Children's Hospital, New York, New York

   Locations

   45 in total

   Run by

   COUR Pharmaceutical Development Company, Inc.

   See if you can join NCT06783309 on ClinicalTrials.gov

3. Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG

   This is a 2-arm, multi-center, open label study to learn if ATG works the same or better than teplizumab in delaying or preventing Stage 3 Type 1 diabetes. Participants will be administered either 2 infusions of ATG or 14 infusions of teplizumab and will then be followed for at least 12-48 months a…

   Stage

   Phase 2

   Ages

   4 to 34

   Site

   Columbia University, New York, New York

   Locations

   6 in total

   Run by

   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

   See if you can join NCT07216391 on ClinicalTrials.gov

4. Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus

   This Phase 2 study is a 2-arm, multi-center, double-masked (masking of the participant, care provider and investigator), placebo-controlled, 2:1 randomized trial design in new onset T1D participants (within 100 days of diagnosis). Participants will be administered rezpegaldesleukin/placebo once eve…

   Stage

   Phase 2

   Ages

   8 to 45

   Site

   Columbia University, New York, New York

   Locations

   15 in total

   Run by

   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

   See if you can join NCT07142252 on ClinicalTrials.gov

5. A Study of GNTI-122 in Adults Recently Diagnosed With T1D

   This is a 78-week single arm, multi-center, Phase 1 study to evaluate the safety, tolerability, cellular kinetics, and biomarker changes in C-peptide over time of GNTI-122, an investigational cell therapy manufactured from a participant's own blood cells in adult participants with recently diagnose…

   Stage

   Phase 1

   Ages

   18 to 55

   Site

   Icahn School of Medicine at Mount Sinai, New York, New York

   Locations

   10 in total

   Run by

   GentiBio, Inc

   See if you can join NCT06919354 on ClinicalTrials.gov